Loxapine(lox’ a peen)
Adasuve
Loxapine Succinate
Apo-Loxapine (CAN), Loxapac (CAN), Loxitane, PMS-Loxapine (CAN)
PREGNANCY CATEGORY C
Drug Classes
Antipsychotic
Dopaminergic blocker
Therapeutic Actions
Indications
Treatment of schizophrenia
NEW INDICATION: Control of agitation related to schizophrenia or bipolar disorder (inhalation)
Contraindications and Cautions
Contraindicated with coma or severe CNS depression; bone marrow depression; blood dyscrasia; circulatory collapse; subcortical brain damage; Parkinson disease; liver disease; cerebral arteriosclerosis; coronary disease; severe hypotension or hypertension; known hypersensitivity to dibenzoxazepines.
Use cautiously with respiratory disorders (“silent pneumonia”); glaucoma, prostatic hypertrophy; epilepsy or history of epilepsy; breast cancer (elevations in prolactin may stimulate a prolactin-dependent tumor); thyrotoxicosis; peptic ulcer, decreased renal function; exposure to heat or phosphorus insecticides; pregnancy; and lactation.
Available Forms
Capsules—5, 10, 25, 50 mg; inhalation—10 mg/single-use inhaler
Dosages
Adults
Oral
Individualize dosage, and administer in divided doses bid–qid; initially, 10 mg bid. Severely disturbed patients may need up to 50 mg/day. Increase dosage fairly rapidly over the first 7–10 days until symptoms are controlled. Usual dosage range is 60–100 mg/day; dosage greater than 250 mg/day is not recommended. For maintenance, reduce to minimum effective dose. Usual range is 20–60 mg/day.
Inhalation
10 mg once daily using single-use inhaler. Must be administered by health care provider in a setting with emergency equipment available.
Pediatric patients
Not recommended for patients younger than 16 yr.
Geriatric patients
Use lower doses, and increase dosage more gradually than in younger patients.
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
